Sera Prognostics, Inc. (SERA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Sera Prognostics, Inc. is a women's health company focused on developing and commercializing blood-based biomarker tests, primarily the PreTRM test, which predicts the risk of preterm birth. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $17,000 | $24,000 | $55,000 | $24,000 |
| Net Loss | $(8,046,000) | $(8,303,000) | $(16,233,000) | $(16,400,000) |
| Loss Per Share (Basic/Diluted) | $(0.16) | $(0.25) | $(0.36) | $(0.50) |
| Cash & Cash Equivalents | $5.0 million (as of June 30, 2025) | |||
| Total Cash, Equivalents & Marketable Securities | $108.5 million (as of June 30, 2025) | |||
| Accumulated Deficit | $(296.0 million) (as of June 30, 2025) |
Note: All financial figures are in thousands unless otherwise noted.
Material Changes vs. Prior Period
- Revenue: Q2 2025 revenue decreased by $7,000 compared to Q2 2024. However, YTD 2025 revenue increased by $31,000 compared to YTD 2024, driven by deferred revenue recognition from prior agreements.
- Operating Expenses: Total operating expenses remained relatively flat quarter-over-quarter ($9.3 million in Q2 2025 vs. $9.3 million in Q2 2024).
- R&D: Decreased by $1.1 million in Q2 2025, primarily due to reduced clinical study costs (PRIME study winding down) and lower stock-based compensation.
- Selling & Marketing: Increased by $0.7 million in Q2 2025 due to strategic hiring of commercial personnel and increased marketing spend in anticipation of PRIME study publication.
- G&A: Increased by $0.4 million in Q2 2025 due to higher personnel costs.
- Liquidity Event: In February 2025, the company completed an underwritten public offering, raising approximately $53.6 million in net proceeds through the sale of Class A common stock and pre-funded warrants. This significantly bolstered cash reserves.
- Investing Activities: The company invested heavily in marketable securities, with net cash used in investing activities totaling $39.6 million for the six months ended June 30, 2025.
Guidance, Outlook, and Risks
- Commercial Strategy: Management is expanding its commercial team, having hired a Chief Commercial Officer in Q2 2025 and planning to hire field sales representatives in Q3 2025. The strategy focuses on specific geographies to drive adoption of the PreTRM test.
- Clinical Evidence: The company recently presented key results from the PRIME study, showing a 25% reduction in neonatal morbidity and mortality in the modified intent-to-treat population. Full data publication is expected in the coming months. Positive results from the AVERT PRETERM TRIAL were also published in July 2024.
- Cash Runway: Management believes current cash and cash equivalents are sufficient to fund operations through 2028 based on existing plans.
- Risks:
- Reimbursement: Significant reliance on third-party payer reimbursement; many payers currently do not reimburse for low-risk preterm birth screening.
- Regulatory: Uncertainty regarding FDA regulation of Laboratory Developed Tests (LDTs), though a recent court decision vacated a final rule that would have imposed stricter requirements.
- Customer Concentration: Reliance on a limited number of direct customers, including Elevance Health.
- Capital Needs: Continued need for additional funding to support commercialization and R&D; future equity financing may be dilutive.
Investor Verification Checklist
- Reimbursement Status: Verify current in-network status and reimbursement rates with major commercial payers and Medicaid programs.
- PRIME Study Publication: Monitor the timeline and reception of the full PRIME study data in peer-reviewed journals.
- Commercial Execution: Track the hiring progress of the sales team and early adoption metrics in targeted geographies.
- Capital Structure: Review the terms and exercise status of the 11.25 million pre-funded warrants issued in February 2025.
- Regulatory Landscape: Monitor ongoing legislative and judicial developments regarding FDA oversight of LDTs.